Sabby Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Sabby Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-31	Closed	-$599K	–	133
2018 Q3	$599K	Sell	31 -130	-81%	-$2.43M	0.08%	69
2018 Q2	$2.76M	Buy	+161	New	+$1.86M	0.43%	36
2014 Q3	–	Sell	-22	Closed	-$306K	–	273
2014 Q2	$306K	Hold	22	–	–	0.01%	209
2014 Q1	$360K	Buy	+22	New	+$412K	0.02%	190

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Sabby Management's GLMD Position: Q4 2018 in Review

Sabby Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2018, closing a stake of 31 shares — an estimated $599K sold.

Sabby Management first reported a position in GLMD in Q1 2014 and held it in 4 quarters. The position peaked at $2.76M in Q2 2018. 37 funds tracked by Wall St. Rank hold GLMD as of Q4 2018.

Sabby Management reported no remaining Galmed Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Sabby Management sold 31 Galmed Pharmaceuticals shares in Q4 2018, an estimated $599K.
Sabby Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 4 quarters.
Sabby Management's Galmed Pharmaceuticals position peaked at $2.76M in Q2 2018.
37 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.